Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

PURPOSE: The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly i...

Full description

Bibliographic Details
Main Authors:	Nathan, P, Zweifel, M, Padhani, A, Koh, D, Ng, M, Collins, D, Harris, A, Carden, C, Smythe, J, Fisher, N, Taylor, N, Stirling, J, Lu, S, Leach, M, Rustin, G, Judson, I
Format:	Journal article
Language:	English
Published:	2012

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

Similar Items